Jane Street’s ARS Pharmaceuticals SPRY Stock Holding History

Jane Street’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,400	Closed	-$215K	–	12308
2025 Q3	$215K	Sell	21,400 -21,000	-50%	-$301K	﹤0.01%	9539
2025 Q2	$740K	Buy	42,400 +2,800	+7%	+$40.4K	﹤0.01%	6192
2025 Q1	$498K	Buy	+39,600	New	+$476K	﹤0.01%	6871
2024 Q4	–	Sell	-39,900	Closed	-$579K	–	10519
2024 Q3	$579K	Buy	+39,900	New	+$475K	﹤0.01%	6937
2023 Q3	–	Sell	-12,600	Closed	-$84.4K	–	9341
2023 Q2	$84.4K	Buy	+12,600	New	+$84.1K	﹤0.01%	8069

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jane Street's SPRY Position: Q2 2026 in Review

Jane Street opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 17,997 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #10378 among its holdings. This is a return to the name: Jane Street previously reported a position in SPRY as recently as Q3 2025.

Jane Street first reported a position in SPRY in Q4 2020 and has held it in 14 quarters since. The position peaked at $2.43M in Q3 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Jane Street held 17,997 shares of ARS Pharmaceuticals worth $144K as of Q2 2026.
ARS Pharmaceuticals was a new Jane Street position in Q2 2026.
ARS Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10378 holding.
Jane Street first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
Jane Street's ARS Pharmaceuticals position peaked at $2.43M in Q3 2025.
208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.